Publications

Publications List

Including Posters, Abstracts, and Presentations
For more information, or to obtain copies of published work, email: info@bostonhealthcare.com


2016
Brüggenjürgen, B, Andersohn, F, Burkowitz, J, Ezzat, N, Gaudig, M, Willich, SN (2016). Cohort Study on Predictors of Need for Nursing Care in Alzheimer’s Disease: An Analysis of Healthcare Data. Journal of Alzheimer’s Disease. doi: 10.3233/JAD-160137

Burkowitz J, Merzenich, C, Grassme K, Brüggenjürgen B (2016). Insertable Cardiac Monitors in the Diagnosis of Syncope and the Detection of Atrial Fibrillation: A Systematic Review and Meta-Analysis. European Journal of Preventative Cardiology. doi: 10.1177/2047487316632628

Doshi S, Ray D, Stein K, Zhang J, Koduro P, Fogt F, Wellman A, Wat R, Mathews, C (2016). Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer. Diagnostics. doi: 10.3390/diagnostics6010004

Sabatini L, Mathews C, Ptak D, Doshi S, Tynan K, Hedge M, Burke T, Bossler A (2016). Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis. The Journal of Molecular Diagnostics. doi: 10.1016/j.jmoldx.2015.11.010



2015
Aggarwal J, Goss T, Mathews C, Kearney P, Diette G (2015). Budget Impact Model of a Blood Based Proteomic Classifier for Indeterminate Pulmonary Nodules. Presented at the 20th Annual ISPOR International Meeting, Philadelphia, PA, May 18, 2015.

Beaton R, Ferrara J, Rompas S (2015). Digital Health Innovation in the US Value Environment. White Paper.

Rompas S, Goss T, Amanuel S, Victoria Coutinho V, Lai Z, Antonini P, Murphy MF (2015). Demonstrating Value for Biosimilars: A Conceptual Framework. American Health & Drug Benefits. 2015 May; 8(3).

Sweeney N and Goss T (2015). The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time. White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA).



2014
Aggarwal J, Vera-Llonch M, Donepudi M, Suthoff E, Younossi Z and Goss TF. (2014), Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. Journal of Viral Hepatitis. doi: 10.1111/jvh.12227

Association of Community Cancer Centers (ACCC), the Biotechnology Industry Organization (BIO), Boston Healthcare Associates, Inc., and Pharmaceutical Research and Manufacturers of America (PhRMA) (March/April 2014). Physician Survey of Impact of Payer Policies on Medically Appropriate Off-Label Use. Oncology Issues: Journal of the Association of Community Cancer Centers (ACCC).

Bücheler M, Brüggenjürgen B, Willich S (2014). Personalized Medicine In Europe – Enhancing Patient Access To Pharmaceutical Drug-Diagnostic Companion Products. EPEMED: Patient Access Study 2012 – 2013.

Ellwanger E, Kim H, and Goss T (September 2014). The Value of Innovation in HIV/AIDs Therapy. White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA).

Klein G, Lickfett L, Schreieck J, Deneke T, Wieczorek M, for the FAST-PVI Study Group, Burkowitz J, Alvares-Ossorio L, Brüggenjürgen B. Comparison of ‘anatomically designed’ and ‘point-by-point’ catheter ablations for human atrial fibrillation in terms of procedure timing and costs in German hospitals. European Society of Cardiology [accepted ahead of print]. 2014; doi:10.1093/eurospace/euu386.

Su, Betty quoted in Parry, J (September 2014). “China enters the global vaccine market.” Bulletin of the World Health Organization, 92:626–627. doi: http://dx.doi.org/10.2471/BLT.14.020914.

Vachani A, Tanner NT, Aggarwal J, Mathews C, Kearney P, Fang KC, Silvestri G, Diette GB (2014, November 11). Factors That Influence Physician Decision-making for Indeterminate Pulmonary Nodules. Annals of the American Thoracic Society [online ahead of print]; DOI: 10.1513/AnnalsATS.201405-197BC.

Vachani A, Tanner N, Diette G, Aggarwal J, Mathews C, Goss T, Kearney P, Fang K, Silvestri G. A Markov model derived to quantify drivers of decision making in the evaluation of patients with pulmonary nodules. Presented at American Thoracic Society (ATS) Annual Meeting, San Diego, California. May 18-21, 2014.



2013
Augustyn C, Walker B, Goss TF (March 2013). Recognizing the Value of Innovation in the Treatment of Rheumatoid Arthritis. White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA). Click here to read the Executive Summary.

Brüggenjürgen B, Kohler S, Ezzat N, Reinhold T, Willich SN. Cost Effectiveness of Antiarrhythmic Medications in Patients Suffering from Atrial Fibrillation. PharmacoEconomics. 2013; 31(3):195-213.

Fusfeld L, Aggarwal J, Dougher C, Vera-Llonch M, Bubb S, Donepudi M, Goss TF (2013, May). Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infectious Diseases, 13(1):234.

Olchanski N, McInnis Myers M, Halseth M, Cyr PL, Bockstedt L, Goss TF, Howland RH (2013, April). The economic burden of treatment-resistant depression. Clinical Therapeutics, 35(4):512-22. doi: 10.1016/j.clinthera.2012.09.001. Epub 2013 Mar 13.

Sherman KE, Muir A, Aggarwal J, Donepudi M, Goss T, Martin M, Vera-Llonch M, Younossi Z. Health-related quality of life among genotype 1 treatment experienced chronic hepatitis c patients: Post-hoc analyses of data from the REALIZE clinical trial. Presented at 48th Annual meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 24-28, 2013.

Vera-Llonch M, Martin, M, Aggarwal J, Donepudi M, Bayliss M, Goss T, Younossi Z (2013, July). Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Alimentary Pharmacology and Therapeutics, 38(2):124-33. doi: 10.1111/apt.12354. Epub 2013 Jun 3.



2012
Augustyn C, Walker B, Goss TF (December 2012). Recognizing the Value of Innovation in HIV/AIDs Therapy. White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA).

Goss TF quoted in Kean M, Lessor T (Eds.) (2012, June). Sustaining Progress Against Cancer in an Era of Cost Containment Discussion Paper. Feinstein Kean Healthcare; Cambridge, MA. Available at: www.TurningTheTideAgainstCancer.org.

Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF (2012, June). Cost-Effectiveness Model of Use of Genetic Testing as an Aid in Assessing the Likely Benefit of Aspirin Therapy for Primary Prevention of Cardiovascular Disease. Clinical Therapeutics, 34(6):1387-1394.

Brüggenjürgen B, Kornbluth L, Ferrara JV, Willich SN (2012, May). Clinical and health economic challenges of personalized medicine. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 55(5):710-4.

Goss TF, Picard EH, Tarab A (2012, June). Recognizing Value in Oncology Innovation. White Paper: Pharmaceutical Research and Manufacturers of America (PhRMA).

Hernandez N, Vera-Llonch M, Aggarwal J, Donepudi M, Younossi Z, Goss TF. Predictors of days unable to work among genotype 1 treatment-naïve chronic hepatitis C patients: Post-hoc analyses of data from phase 3 ADVANCE and ILLUMINATE studies. Presented at 47th Annual meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain. April 18-22, 2012.

Younossi Z, Aggarwal J, Martin M, Hernandez N, Donepudi M, Bayliss M, Goss TF, Vera-Llonch M. Health-related quality of life among genotype 1 treatment-naïve chronic hepatitis c patients receiving telaprevir combination treatment: Post-hoc analyses of data from the ADVANCE Trial. Presented at 47th Annual meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain. April 18-22, 2012.

Ferrara J quoted in Roberts JP (2012, Feb 15). Molecular Diagnostic Alliances Increasingly the Norm. Genetic Engineering & Biotechnology News. 32(4).



2011

Ferrara J quoted in Roberts JP (2012, Feb 15). Molecular Diagnostic Alliances Increasingly the Norm. Genetic Engineering & Biotechnology News. 32(4).

Mathews M quoted in Herriman LEJ (Ed.) (2011). Creating a Value-Drive Laboratory: Opportunities in the New Marketplace. Peterborough, NH: G2 Intelligence.

Parker D, Ehreth J, Eldessouki R, & Faulkner E (2011). “Chapter 3: Therapeutic and Diagnostic Device Research and Development: An Overview” In Ackerman S, Smith MD, Ehreth J, Eldessouki R, & Sullivan E (Eds.), Therapeutic and Diagnostic Device Outcomes Research. Lawrenceville, NJ: ISPOR.

Parker D (2011). “Chapter 4: Therapeutic and Diagnostic Device Clinical Development Costs” In Ackerman S, Smith MD, Ehreth J, Eldessouki R, & Sullivan E (Eds.), Therapeutic and Diagnostic Device Outcomes Research. Lawrenceville, NJ: ISPOR.

Parker D (2011). “Chapter 19: Drug-Device Combination: Companion Diagnostics” In Ackerman S, Smith MD, Ehreth J, Eldessouki R, & Sullivan E (Eds.), Therapeutic and Diagnostic Device Outcomes Research. Lawrenceville, NJ: ISPOR.

Dijkgraaf M, Parker D, & Ehreth J (2011). “Chapter 24: Economic Environment for Therapeutic and Diagnostic Devices” In Ackerman S, Smith MD, Ehreth J, Eldessouki R, & Sullivan E (Eds.), Therapeutic and Diagnostic Device Outcomes Research. Lawrenceville, NJ: ISPOR.

Ferrara J quoted in Weisman R (2011, Oct 22). Mid-size biotechs making their way. The Boston Globe.

Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, & Goss TF (2011, September). A Structured Literature Review of the Direct Costs of Adult Systemic Lupus Erythematosus in the US. Arthritis Care & Research. 63(9):1224–1232.

Mathews M quoted in Maroney M (2011, June). Personalized Medicine: Challenges to Market Access. IMS Health Pharma Pricing and Reimbursement. 16(6):176-179.

Fusfeld L, Goss TF, Finch J (2011, May). Budget Impact Model for RNATesting with HPV OncoTect® for High-Risk HPV. Presented at Eurogin International Multidisciplinary Conference, Lisbon, Portugal.

Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, Askaa J, Larcier P, Terry PF, Bruinvels A, & Huriez A (March 2011). Market Access Challenges in the EU for High Medical Value Diagnostic Tests. Future Medicine: Journal of Personalized Medicine. 8(2):137-148.

Olchanski N, Mathews C, Fusfeld L, & Jarvis W (2011, March). Assessment of the Influence of Test Characteristics on the Clinical and Cost Impacts of Methicillin-Resistant Staphylococcus aureus Screening Programs in US Hospitals. Infection Control and Hospital Epidemiology. 32(3):250-257.

Cyr PL, Slawsky KA, Olchanski N, Krasa HB, Goss TF, Zimmer C, & Hauptman PJ (2011, February 15). Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health-System Pharmacy. 68(4):328-333. 2010



2010

Parker D (2010, December 7). The Adverse Impact of the US Reimbursement System on the Development and Adoption of Personalized Medicine Diagnostics. Personalized Medicine Coalition (PMC). Issue Brief.

McInnis MM, Halseth MJ, Cyr P, Howland RH, Bockstedt Santiago L, & Goss T (2010, November). Burden of Illness of Treatment Resistant Depression. Presented at ISPOR 13th Annual European Congress, Czech Republic, Prague.

McInnis MM, Olchanski N, Kemner JE, & Goss T (2010, November). Budget Impact of New RHBMP-2 Formulation in Patients Undergoing Posterola Spinal Fusion Procedures for Degenerative Disc Disease in Randomized Controlled Trial (RCT). Presented at ISPOR 13th Annual European Congress, Czech Republic, Prague.

Lanman R, Kennedy G, Olchanski N, Mathews C, Wang C, & Ladenson P (2010, June). Economic Impact of a Novel Molecular Diagnostic Test in Evaluation of Thyroid Nodules with Indeterminate FNA Cytology Results. Abstract presented at The Endocrine Society’s 92nd Meeting & Expo. Endocrine Reviews. Supplement 1, 31(3):S617.

Slawsky K, Goss TF, Shinkle R, & Xu X. (2010, June). Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL): A review of the literature. Journal of Clinical Oncology 28, 2010 (suppl; abstr e18564). Accepted for publication at 2010 ASCO Annual Meeting.

Olchanski N, Slawsky K, Cyr P, & Schwenkglenks M (2010, May 19). Budget Impact of Bivalirudin in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention (PPCI) in Italian Hospitals. Presented at the 15th Annual ISPOR International Meeting, Atlanta GA.

Olchanski N, Slawsky K, Cyr P, Schwenkglenks M, & Steinhubl S (2010, May 19). A French Hospital Budget Impact Model Comparing Anticoagulation Strategies in Primary Percutaneous Coronary Intervention. Presented at the 15th Annual ISPOR International Meeting, Atlanta GA.

Olchanski N, Slawsky K, Cyr P, Schwenkglenks M, & Steinhubl S (2010, May 19). Clinical and Economic Impact of Bivalirudin on Bleeding Events in High Risk Unstable Angina (UA)/Non-ST-Elevation Myocardial Infarction (NSTEMI) Patients Undergoing Percutaneous Coronary Intervention (PCI) in France. Presented at the 15th Annual ISPOR International Meeting, Atlanta GA.

Olchanski N, Slawsky K, Cyr P, Schwenkglenks M, & Zeymer U (2010, May 19). Budget Impact of Bivalirudin in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention (PPCI) in German Hospitals. Presented at the 15th Annual ISPOR International Meeting, Atlanta GA.

Morton J, Anastassopoulos K, Patel S, Lerner J, Ryan K, Goss T, & Dodd S. Frequency and Outcomes of Blood Products Transfusion Across Procedures and Clinical Conditions Warranting Inpatient Care: An Analysis of the 2004 Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database. American Journal of Quality 2010. 25(4):289-296.

Chan S, Slawsky K, Prottas C, Feldmann J, & Goss T (March 2010). Recognizing Value in Oncology Innovation. White Paper.

Weber PA, Wirostko BM, Xu X, Goss TF, & Zlateva G. Newly Diagnosed Exudative Age-Related Macular Degeneration Treated With Pegaptanib Sodium Monotherapy in US Community-Based Practices: Medical Chart Review Study. BMC Ophthalmology 2010. 10(2), In Press.



2009

Cyr P, McInnis M, Slawsky K, Krasa H, Czerwiec F, Ouyang J, Goss T, & Verbalis J (2009, October 24-27). Impact of Tolvaptan on Self-Reported Utility Scores in Hyponatremic Patients. Abstract presented at the ISPOR 12th Annual European Congress, Paris, France.

Cyr P, Slawsky K, Krasa H, Zimmer C, Ouyang J, Goss T, Udelson J, & Hauptman P (2009, October 24-27). Effect of Tolvaptan on Hospital Length of Stay within Hyponatremic Patients Hospitalized for Heart Failure. Abstract presented at the ISPOR 12th Annual European Congress, Paris, France.

Cyr P, Slawsky K, Krasa H, Zimmer C, Ouyang J, Goss T, Udelson J, & Hauptman P (2009, October 24-27). Evaluation of the Association Between Serum Sodium and Length of Stay in Patients Hospitalized for Heart Failure. Abstract presented at the ISPOR 12th Annual European Congress, Paris, France.

Schwenkglenks M, Szucs TD, Brazier J, Blackman D, Cyr P, Olchanski N, & Stone GW (2009, October 24-27). Cost-Effectiveness of Bivalirudin versus Heparin Plus Glycoprotein IIb/IIIa Inhibitor in the Treatment of Acute ST-Segment Elevation Myocardial Infarction – A Horizons Trial Analysis Using UK Valuations. Abstracted presented at the ISPOR 12th Annual European Congress, Paris, France.

Olchanski N, Slawsky K, Cyr PL, Schwenkglenks M, & Kinnaird T (2009, October 26). Budget Impact of Bivalirudin in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention (PPCI) in UK Hospitals. Presented at the 12th Annual ISPOR European Congress, Paris, France.

Olchanski N, Slawsky K, Fusfeld L, Cyr PL, Schwenkglenks M, Möckel M, & Zeymer U (2009, October 26). A German Hospital Budget Impact Model Comparing Anticoagulation Strategies in Percutaneous Coronary Intervention. Presented at the 12th Annual ISPOR European Congress, Paris, France.

Mathews C quoted in Perriello B (2009, October 1). MassDevice Q&A: Charles Mathews. Massachusetts Medical Devices Journal LLC. Published on MassDevice at www.massdevice.com.

Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lubbert M, Deschler B, Fenaux P, Mufti GJ, Killick S, & List AF (2009, September 8). Valuation of Transfusion-free Living in MDS: Results of Health Utility Interviews with Patients. Health and Quality of Life Outcome 2009. 7(81), doi:10.1186/1477-7525-7-81.

Mathews C, Geldart T, & McInnis M (2009, August 31). Improving Healthcare Through Diagnostics: The Future of IVDs. Clinica Diagnostics. 50, 1-5.

Slawsky K (2009, August 17). Methods of Value Demonstration in IVD Technology. Clinica Diagnostics. 49, 1-5.

Slawsky K (2009, August 3). Changing Evidentiary Standards: Growth of the IVD Market and Heightened Evidence Requirements. Clinica Diagnostics. 48, 1-5.

Parker D & Walker B (2009, July 20). Capturing the Value of Traditional In Vitro Diagnostic Tests. Clinica Diagnostics. 47, 1-5.

Mathews C (2009, July 6). Cost-Savings or Value Capture: IVD Industry at a Crossroads. Clinica Diagnostics. 46, 1-5.

Cyr P, Bockstedt L, Olchanski N, Halseth M, Partlow K, Lindeke C, Handke B, & Goss T (2009, May 20). A Systematic Evaluation of Published Literature to Assess Burden of Treatment-Resistant Depression. Presented at the 14th Annual ISPOR International Meeting, Orlando, Florida.

Chan S quoted in Fontanazza M (2009, Spring). Q&A: Where Evidence Is King. Med-Tech Precision. 2(1), 18-19.

Morton J, Patel ST, Anastassopoulos KP, Lerner JH, Ryan KJ, Goss TF, & Dodd SL. Prevalence and Outcomes of Blood Transfusion Across Procedures and Clinical Conditions Warranting Inpatient Care: An Analysis of the 2004 Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database. American Journal of Medical Quality. In Press.



2008

Brandenburg NA, Goss TF, Knight T, Xu X, & Knight RD (2008, December 7). Evaluation of the Relationship Between Venous Thromboembolism Risk Factors and the Use of Antithrombotic Prophylaxis in Multiple Myeloma Patients Treated with Thalidomide and Dexamethasone Combination Regimens. American Society of Hematology (ASH) Annual Meeting Abstracts 2008, 112: 2369.

Chan S quoted in Steinke S (2008, December). Experimental Cost Controls: Plans Moving Doctor-Administered Drugs from Medical to Pharmacy Benefit. CMS Beat as published in The RPM Report. 3(17).

Patel ST, Anastassopoulos K, Lerner J, Ryan K, Dodd SL, Goss TF, & Morton J (2008, November 8-11). Clinical and Economic Outcomes Associated with Blood Transfusion during Inpatient Hospitalization: An Analysis of the 2004 Health Care Cost and Utilization Project Nationwide Inpatient Sample Database. Presented at ISPOR Eleventh Annual European Congress. Value in Health 2008.

Xu X, Barron RL, Mautner B, & Goss TF (2008, November 8-11). Association between Respondent- and Practice-related Characteristics and Oncology Staff-reported Burden on Mucositis Management for Head and Neck Cancer (HNC) Patients. Presented at ISPOR Eleventh Annual European Congress. Value in Health 2008.

Xu, X, Barron RL, Mautner B, Ryan K, & Goss TF (2008, September 21-25). Burden of Mucositis Management on Radiation Oncology Facility Staff Treating Head and Neck Cancer Patients. Presented at The American Society for Therapeutic Radiology and Oncology (ASTRO) 50th Annual Meeting, Boston, MA.

James AH, Patel ST, Watson W, Zaidi QR, Mangione A, & Goss TF (2008). An Assessment of Medical Resource Utilization and Hospitalization Cost Associated with a Diagnosis of Anemia in Women with Obstetrical Bleeding in the United States. Journal of Women’s Health. 17, 1279-1284.

Lerner J, Patel ST, & Goss TF (2008, May 5). A Prevalence-Based Economic Analysis of the Growth in Cancer Treatment Spending in the United States. Presented at ISPOR Thirteenth Annual Meeting. Value in Health 2008, 11(3), A82.

Morrison J, Patel ST, Watson W, Zaidi QR, Mangione A, & Goss TF (2008). Assessment of the Prevalence and Impact of Anemia on Women Hospitalized for Gynecologic Conditions Associated With Heavy Uterine Bleeding. Journal of Reproductive Medicine. 53, 323–330.

Schaefer C, Lerner J, Santillo C, & Goss T (2008, May 5). The Role of the Academy of Managed Care Pharmacy (AMCP) Format in Managed Care Formulary and Coverage Decisionmaking. Presented at ISPOR Thirteenth Annual Meeting. Value in Health 2008, 11(3) A48.

Cruess A, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Monès J, Buggage R, Schaefer C, Knight T, & Goss T (2008). Economic Burden of Neovascular Age-Related Macular Degeneration: A Multi-country Study. Pharmacoeconomics. 26(1), 57-73.